{ "company": "Hologic", "ticker": "HOLX", "period": { "from": "2026-02-28", "to": "2026-03-30", "days": 30 }, "sentiment_breakdown": { "positive": 50, "negative": 30, "neutral": 64 }, "synthesis": { "executive_summary": "**Executive Summary: Hologic (HOLX) Sentiment Analysis (February 28 - March 30, 2026)**\n\nSentiment analysis for Hologic (HOLX) during the period of February 28 to March 30, 2026, indicates a net-positive outlook, characterized by a higher volume of positive news items compared to negative, despite a significant neutral component. Out of 144 analyzed items, 50 were positive, 30 were negative, and 64 were neutral. Key positive drivers include fresh institutional interest, exemplified by Pensionfund Sabic's acquisition of 18,800 HOLX shares, signaling confidence in the company's long-term growth and position as a women's health diagnostics leader. Additionally, broader market opportunities in medical image analysis software, projected to reach $4.35 billion, and the evolving COVID-19 tests market, present favorable industry tailwinds for Hologic's portfolio.\n\nConversely, negative sentiment largely stemmed from research highlighting ongoing challenges within women's health. Several academic publications focused on racial disparities in breast cancer symptom burden and complexities in breast and cervical cancer screening and diagnosis methodologies. Notably, a news report detailing the mammography devices market's projected growth to $3.81 billion by 2030 also registered as negative sentiment, suggesting underlying concerns or competitive pressures within this expanding market segment. Overall, while positive developments related to institutional confidence and market opportunities are prominent, the data also reflects persistent challenges in healthcare delivery and diagnostics.", "key_findings": [ "✓ Medical Image Analysis Software Global Forecast 2026-2032: $4.35 Bn Opportunities Driven by Enhancing Clinical Workflows, Boosting Diagnostic Accuracy, and Fostering Partnerships to Drive AI Adoption", "✓ Masimo Corp Stock: Innovative Medical Tech Leader with Strong Growth Potential for North American In", "✓ COVID-19 Tests Market Report 2025: Segments, Share, Regulatory, Reimbursement, and Forecasts to 2036", "✗ Potential role of perceived discrimination and sociodemographics on racial disparities in breast cancer symptom burden.", "✗ Mammography Devices Market to Reach $3.81 Billion by 2030, Driven by Technological Advancements and Rising Breast Cancer Awareness", "✗ Dual-modality CAD for breast cancer screening: dealing with discordant diagnosis between mammography and tomography." ], "overall_sentiment": "positive" }, "top_positive": [ { "title": "Medical Image Analysis Software Global Forecast 2026-2032: $4.35 Bn Opportunities Driven by Enhancing Clinical Workflows, Boosting Diagnostic Accuracy, and Fostering Partnerships to Drive AI Adoption", "date": "2026-03-05", "source": "news", "score": 1.0 }, { "title": "Masimo Corp Stock: Innovative Medical Tech Leader with Strong Growth Potential for North American In", "date": "2026-03-29", "source": "alpha_vantage", "score": 1.0 }, { "title": "COVID-19 Tests Market Report 2025: Segments, Share, Regulatory, Reimbursement, and Forecasts to 2036", "date": "2026-03-12", "source": "news", "score": 0.859 }, { "title": "Hologic stock sees fresh institutional interest as Pensionfund Sabic buys 18,800 shares amid medical", "date": "2026-03-26", "source": "alpha_vantage", "score": 0.758 }, { "title": "Hologic stock sees fresh institutional interest as Pensionfund Sabic buys 18,800 shares amid medical", "date": "2026-03-26", "source": "alpha_vantage", "score": 0.758 }, { "title": "Handing off hope: transition of care in pediatric surgery.", "date": "2026 Mar 2", "source": "pubmed", "score": 0.727 }, { "title": "Mammography Devices Market Poised for Robust Growth at 8.25%", "date": "2026-03-18", "source": "alpha_vantage", "score": 0.718 }, { "title": "Global Women's Health Shows Signs of Progress; Gaps Remain", "date": "2026-03-17", "source": "news", "score": 0.7 }, { "title": "U.S. Exosomes Market to Skyrocket During 2026-2033, Reaching $716.8 Million - Analysis of Lucrative Business Opportunities and Key Players; Danaher, Thermo Fisher Scientific, Hologic, Fujifilm, Lonza and More", "date": "2026-03-20", "source": "news", "score": 0.681 }, { "title": "HOLX Stock Gains on FDA & CE Approval for Automated Molecular GI Tests", "date": "2026-03-16", "source": "alpha_vantage", "score": 0.67 } ], "top_negative": [ { "title": "Potential role of perceived discrimination and sociodemographics on racial disparities in breast cancer symptom burden.", "date": "2026 Mar 1", "source": "pubmed", "score": -0.807 }, { "title": "Mammography Devices Market to Reach $3.81 Billion by 2030, Driven by Technological Advancements and Rising Breast Cancer Awareness", "date": "2026-03-27", "source": "news", "score": -0.727 }, { "title": "Dual-modality CAD for breast cancer screening: dealing with discordant diagnosis between mammography and tomography.", "date": "2026-03-30", "source": "pubmed", "score": -0.66 }, { "title": "Recent Trends in Whole-Breast Irradiation Versus Partial-Breast Irradiation in Ductal Carcinoma in situ with Breast-Conserving Surgery 2011-2021: A National Cancer Database Study.", "date": "2026 Mar 2", "source": "pubmed", "score": -0.66 }, { "title": "Clinical performance of ASCL1/LHX8 DNA methylation on first-void urine to screen for cervical cancer.", "date": "2026 Mar 1", "source": "pubmed", "score": -0.66 }, { "title": "Targeted axillary dissection in breast cancer: current evidence and ongoing trials.", "date": "2026-03-30", "source": "pubmed", "score": -0.66 }, { "title": "DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer.", "date": "2026 Mar 1", "source": "pubmed", "score": -0.66 }, { "title": "Finding the optimal recall rate in breast cancer screening: results from the ROCS study.", "date": "2026 Mar 5", "source": "pubmed", "score": -0.64 }, { "title": "Biopsy Devices Market Size Projected to Reach USD 5.08 Billion by 2035; Increasing Incidence of Cancer to Drive Market Growth Globally – SNS Insider", "date": "2026-03-20", "source": "news", "score": -0.572 }, { "title": "A repeat expansion in GOLGA8A is a major risk factor for atypical frontotemporal lobar degeneration with ubiquitin-positive inclusions", "date": "2026-03-12", "source": "news", "score": -0.541 } ], "raw_data": { "total_items": 144, "items": [ { "source": "news", "source_name": "Financial Post", "title": "Inside ‘Project Eagle,’ JPMorgan’s High-Wire Act to Fund EA Deal", "description": "The post from @realDonaldTrump landed at precisely 7:23 a.m. Inside JPMorgan Chase & Co., the final piece of Project Eagle was a go.", "url": "https://financialpost.com/pmn/business-pmn/inside-project-eagle-jpmorgans-high-wire-act-to-fund-ea-deal", "date": "2026-03-28", "published_at": "2026-03-28T19:38:06Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Mammography Devices Market to Reach $3.81 Billion by 2030, Driven by Technological Advancements and Rising Breast Cancer Awareness", "description": "Key market opportunities include advancements in digital and 3D mammography, integration of AI and CAD systems, expansion of portable units, and increased government support for early breast cancer detection. Growth in Asia-Pacific and rising breast cancer pr…", "url": "https://www.globenewswire.com/news-release/2026/03/27/3263847/28124/en/Mammography-Devices-Market-to-Reach-3-81-Billion-by-2030-Driven-by-Technological-Advancements-and-Rising-Breast-Cancer-Awareness.html", "date": "2026-03-27", "published_at": "2026-03-27T14:30:00Z", "sentiment": { "label": "negative", "score": -0.727, "confidence": 0.73 } }, { "source": "news", "source_name": "Pehub.com", "title": "Women’s health ripe for private equity investments, finds Kearney’s Paula Bellostas Muguerza", "description": "Blackstone and TPG's $18.3bn take-private of Hologic, which is expected to close soon, is a bellwether.\nThe post Women’s health ripe for private equity investments, finds Kearney’s Paula Bellostas Muguerza appeared first on PE Hub.", "url": "https://www.pehub.com/?p=20000003725583", "date": "2026-03-26", "published_at": "2026-03-26T16:00:53Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Pypi.org", "title": "dicom-hl7-mcp added to PyPI", "description": "DICOM/HL7 Developer AI Assistant — MCP server for healthcare integration engineers", "url": "https://pypi.org/project/dicom-hl7-mcp/", "date": "2026-03-25", "published_at": "2026-03-25T17:27:47Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "New York Post", "title": "Iga Swiatek parts ways with tennis coach after stunning loss: ‘Worst nightmare’", "description": "Polish tennis star Iga Swiatek has parted ways with her coach, Wim Fissette, who joined in her 2024, after a \"nightmare\" second-round loss at the 2026 Miami Open.", "url": "https://nypost.com/2026/03/23/sports/iga-swiatek-parts-ways-with-tennis-coach-after-stunning-loss-worst-nightmare/", "date": "2026-03-23", "published_at": "2026-03-23T20:55:06Z", "sentiment": { "label": "negative", "score": -0.45, "confidence": 0.45 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Biopsy Devices Market Size Projected to Reach USD 5.08 Billion by 2035; Increasing Incidence of Cancer to Drive Market Growth Globally – SNS Insider", "description": "Rising Demand for Minimally Invasive, Image-Guided Procedures and Expanding Healthcare Infrastructure Accelerate Global Market Expansion. Rising Demand for Minimally Invasive, Image-Guided Procedures and Expanding Healthcare Infrastructure Accelerate Global M…", "url": "https://www.globenewswire.com/news-release/2026/03/20/3259711/0/en/Biopsy-Devices-Market-Size-Projected-to-Reach-USD-5-08-Billion-by-2035-Increasing-Incidence-of-Cancer-to-Drive-Market-Growth-Globally-SNS-Insider.html", "date": "2026-03-20", "published_at": "2026-03-20T12:14:00Z", "sentiment": { "label": "negative", "score": -0.572, "confidence": 0.57 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "U.S. Exosomes Market to Skyrocket During 2026-2033, Reaching $716.8 Million - Analysis of Lucrative Business Opportunities and Key Players; Danaher, Thermo Fisher Scientific, Hologic, Fujifilm, Lonza and More", "description": "Dublin, March 20, 2026 (GLOBE NEWSWIRE) -- The \"U.S. Exosomes Market Size, Share & Trends Analysis Report by Product & Service, Application, Workflow, End Use, and Segment Forecasts, 2026-2033\" has been added to ResearchAndMarkets.com's offering.The U.S. exos…", "url": "https://www.globenewswire.com/news-release/2026/03/20/3259642/28124/en/U-S-Exosomes-Market-to-Skyrocket-During-2026-2033-Reaching-716-8-Million-Analysis-of-Lucrative-Business-Opportunities-and-Key-Players-Danaher-Thermo-Fisher-Scientific-Hologic-Fujif.html", "date": "2026-03-20", "published_at": "2026-03-20T10:45:00Z", "sentiment": { "label": "positive", "score": 0.681, "confidence": 0.68 } }, { "source": "news", "source_name": "Forbes", "title": "Why Alexandra Eala Could Be Tennis’ Next Global Trailblazer", "description": "This story is about Alexandra Eala, seeded No. 31 at the Miami Open, and her potential to become the next trailblazing superstar in tennis.", "url": "https://www.forbes.com/sites/merlisalawrencecorbett/2026/03/19/why-alexandra-eala-could-be-tennis-next-global-trailblazer/", "date": "2026-03-19", "published_at": "2026-03-19T20:23:40Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Nature.com", "title": "AI-based triage and decision support in mammography and digital tomosynthesis for breast cancer screening: a paired, noninferiority trial", "description": "The breast cancer screening trial found that using automated artificial intelligence to triage and support decisions in mammography and digital breast tomosynthesis was not noninferior to double reading.", "url": "https://www.nature.com/articles/s41591-026-04277-x", "date": "2026-03-19", "published_at": "2026-03-19T00:00:00Z", "sentiment": { "label": "negative", "score": -0.318, "confidence": 0.32 } }, { "source": "news", "source_name": "Plos.org", "title": "Association between vaginal washing and group B Streptococcus colonization from periconception through the first trimester of pregnancy in a cohort of Kenyan women", "description": "Introduction Vaginal washing has been associated with adverse reproductive health outcomes including pelvic inflammatory disease, reduced fecundability, and HIV acquisition. This analysis tested the hypothesis that vaginal washing is associated with increased…", "url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0344736", "date": "2026-03-18", "published_at": "2026-03-18T14:00:00Z", "sentiment": { "label": "negative", "score": -0.161, "confidence": 0.16 } }, { "source": "news", "source_name": "Yahoo Entertainment", "title": "Is Hologic Stock Outperforming the Dow?", "description": "", "url": "https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_19e412a8-8d41-4673-889f-d27d85333fe7", "date": "2026-03-18", "published_at": "2026-03-18T13:59:04Z", "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "news", "source_name": "Gallup.com", "title": "Global Women's Health Shows Signs of Progress; Gaps Remain", "description": "The fifth Hologic Global Women's Health Index shows progress in preventive care and safety, but gaps remain.", "url": "https://news.gallup.com/poll/702947/global-women-health-shows-signs-progress-gaps-remain.aspx", "date": "2026-03-17", "published_at": "2026-03-17T04:01:00Z", "sentiment": { "label": "positive", "score": 0.7, "confidence": 0.7 } }, { "source": "news", "source_name": "Cdc.gov", "title": "Interim Estimates of 2025–26 Seasonal Influenza Vaccine Effectiveness — United States, September 2025–February 2026", "description": "This report describes interim estimates of 2025-26 seasonal flu vaccine effectiveness.", "url": "https://www.cdc.gov/mmwr/volumes/75/wr/mm7509a2.htm", "date": "2026-03-12", "published_at": "2026-03-12T17:23:11Z", "sentiment": { "label": "positive", "score": 0.052, "confidence": 0.05 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Global In Vitro Diagnostics Market to Reach USD 157.63 Billion by 2030 | MarketsandMarkets™", "description": "Market Expansion Accelerates as Clinical Laboratories and Healthcare Systems Prioritize Rapid Diagnostics, Automation, and Early Disease Detection Market Expansion Accelerates as Clinical Laboratories and Healthcare Systems Prioritize Rapid Diagnostics, Autom…", "url": "https://www.globenewswire.com/news-release/2026/03/12/3254849/0/en/Global-In-Vitro-Diagnostics-Market-to-Reach-USD-157-63-Billion-by-2030-MarketsandMarkets.html", "date": "2026-03-12", "published_at": "2026-03-12T14:30:00Z", "sentiment": { "label": "neutral", "score": 0.026, "confidence": 0.03 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "COVID-19 Tests Market Report 2025: Segments, Share, Regulatory, Reimbursement, and Forecasts to 2036", "description": "Opportunities in the COVID-19 tests market include developing innovative products, leveraging global and regional trends, understanding competitive dynamics, and accessing country-specific regulatory and reimbursement insights. Companies can capitalize on mar…", "url": "https://www.globenewswire.com/news-release/2026/03/12/3254589/28124/en/COVID-19-Tests-Market-Report-2025-Segments-Share-Regulatory-Reimbursement-and-Forecasts-to-2036.html", "date": "2026-03-12", "published_at": "2026-03-12T12:04:00Z", "sentiment": { "label": "positive", "score": 0.859, "confidence": 0.86 } }, { "source": "news", "source_name": "Nature.com", "title": "A repeat expansion in GOLGA8A is a major risk factor for atypical frontotemporal lobar degeneration with ubiquitin-positive inclusions", "description": "Genome-wide analysis coupled with long-read sequencing identifies a repeat expansion in GOLGA8A associated with high risk for atypical frontotemporal lobar degeneration with ubiquitin-positive inclusions.", "url": "https://www.nature.com/articles/s41588-026-02537-7", "date": "2026-03-12", "published_at": "2026-03-12T00:00:00Z", "sentiment": { "label": "negative", "score": -0.541, "confidence": 0.54 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Biomarker Testing Market Projected to Reach USD 50.76 Billion by 2035, Driven by Personalized Medicine and Oncology Advancements – SNS Insider", "description": "The global market, valued at USD 32.69 billion in 2025, is set to grow at a CAGR of 4.51% as demand for early disease detection and precision diagnostics surges worldwide. The global market, valued at USD 32.69 billion in 2025, is set to grow at a CAGR of 4.5…", "url": "https://www.globenewswire.com/news-release/2026/03/10/3252520/0/en/Biomarker-Testing-Market-Projected-to-Reach-USD-50-76-Billion-by-2035-Driven-by-Personalized-Medicine-and-Oncology-Advancements-SNS-Insider.html", "date": "2026-03-10", "published_at": "2026-03-10T09:24:00Z", "sentiment": { "label": "positive", "score": 0.66, "confidence": 0.66 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Global Point-of-Care Molecular Diagnostics Market Projected to Reach USD 13.05 Billion by 2035; Growth is Driven by Increasing Need for Fast Near-Patient Testing Globally – SNS Insider", "description": "Growing Adoption of PCR-Based Platforms, Isothermal Amplification Technologies, and Lab-on-a-Chip Systems Accelerating Market Expansion Globally. Growing Adoption of PCR-Based Platforms, Isothermal Amplification Technologies, and Lab-on-a-Chip Systems Acceler…", "url": "https://www.globenewswire.com/news-release/2026/03/09/3251747/0/en/Global-Point-of-Care-Molecular-Diagnostics-Market-Projected-to-Reach-USD-13-05-Billion-by-2035-Growth-is-Driven-by-Increasing-Need-for-Fast-Near-Patient-Testing-Globally-SNS-Inside.html", "date": "2026-03-09", "published_at": "2026-03-09T11:51:00Z", "sentiment": { "label": "positive", "score": 0.625, "confidence": 0.62 } }, { "source": "news", "source_name": "PR Newswire UK", "title": "Global Companion Diagnostics Market to Register Immense Growth at a CAGR of ~12% by 2032 | DelveInsight", "description": "The growth of the companion diagnostics market is largely driven by the sharp worldwide rise in cancer incidence. Increasing awareness of precision medicine among patients, along with manufacturers' expanding efforts to advance precision-based treatments, has…", "url": "https://www.prnewswire.co.uk/news-releases/global-companion-diagnostics-market-to-register-immense-growth-at-a-cagr-of-12-by-2032--delveinsight-302704875.html", "date": "2026-03-05", "published_at": "2026-03-05T22:31:00Z", "sentiment": { "label": "negative", "score": -0.052, "confidence": 0.05 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Medical Image Analysis Software Global Forecast 2026-2032: $4.35 Bn Opportunities Driven by Enhancing Clinical Workflows, Boosting Diagnostic Accuracy, and Fostering Partnerships to Drive AI Adoption", "description": "Opportunities lie in enhancing clinical workflows, boosting diagnostic accuracy, and fostering partnerships to drive AI adoption in medical imaging, amidst evolving regulatory and technological landscapes. Opportunities lie in enhancing clinical workflows, bo…", "url": "https://www.globenewswire.com/news-release/2026/03/05/3249923/28124/en/Medical-Image-Analysis-Software-Global-Forecast-2026-2032-4-35-Bn-Opportunities-Driven-by-Enhancing-Clinical-Workflows-Boosting-Diagnostic-Accuracy-and-Fostering-Partnerships-to-Dr.html", "date": "2026-03-05", "published_at": "2026-03-05T10:29:00Z", "sentiment": { "label": "positive", "score": 1.0, "confidence": 1.0 } }, { "source": "alpha_vantage", "title": "Masimo Corp Stock: Innovative Medical Tech Leader with Strong Growth Potential for North American In", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/masimo-corp-stock-innovative-medical-tech-leader-with-strong-growth/69024469", "date": "2026-03-29", "summary": "Masimo Corp is highlighted as a leading innovator in noninvasive patient monitoring, offering robust growth potential for North American investors. The article details its core business model, technological leadership in pulse oximetry and advanced sensors, and strong market positioning against competitors. It also covers the company's financial health, innovation pipeline, and strategic outlook, while acknowledging risks inherent in the medtech industry.", "sentiment_score": 0.145843, "sentiment_label": "Neutral", "relevance_score": 0.568173, "sentiment": { "label": "positive", "score": 1.0, "confidence": 1.0 } }, { "source": "alpha_vantage", "title": "Hologic stock consolidates as company recognized among America's most charitable firms", "url": "https://tradersunion.com/news/companies/show/1816666-hologic-slips-0-03percent-today-at/", "date": "2026-03-29", "summary": "Hologic's stock is consolidating around new highs, currently trading at $75.67, amidst its recognition on Newsweek's list of America's Most Charitable Companies for its dedication to women's health, STEM, and education. Technical analysis indicates a strong bullish trend with price above key moving averages, though some oscillators suggest potential overbought conditions. The stock has risen 0.34% over the past week and is expected to trade between $75.70 and $75.92 in the coming week, with a hi", "sentiment_score": 0.327018, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.458, "confidence": 0.46 } }, { "source": "alpha_vantage", "title": "Assessing Hologic (HOLX) Valuation After A 21% One Year Shareholder Return", "url": "https://www.sahmcapital.com/news/content/assessing-hologic-holx-valuation-after-a-21-one-year-shareholder-return-2026-03-27", "date": "2026-03-28", "summary": "Hologic (HOLX) has seen a 21% shareholder return over the past year, with shares currently trading around US$75.69. Despite this performance, Simply Wall St's analysis suggests the stock is slightly undervalued, with a fair value estimated at $76.67 per share. The valuation takes into account long-term growth drivers in women's health and diagnostics, but acknowledges potential risks like tariff costs and pressure in international markets.", "sentiment_score": 0.28016, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Align Technology (ALGN) $4.0B 2025 revenue, board refreshment and 2026 proxy", "url": "https://www.stocktitan.net/sec-filings/ALGN/pre-14a-align-technology-inc-preliminary-proxy-statement-963d2a9a5342.html", "date": "2026-03-27", "summary": "Align Technology's 2026 Proxy Statement details its 2025 financial results, including $4.0 billion in net revenues, and outlines strategic priorities such as international expansion and AI-enabled treatment enhancements. The company is also proposing governance changes, including board refreshment and adjustments to executive compensation to better align with stockholder interests. Stockholders will vote on these proposals, as well as the election of ten directors and the ratification of the ind", "sentiment_score": 0.132406, "sentiment_label": "Neutral", "relevance_score": 0.601885, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "ALGN (Align Technology) Net Change in Cash : $51 Mil (TTM As of Dec. 2025)", "url": "https://www.gurufocus.com/term/Net+Change+in+Cash/NAS:ALGN", "date": "2026-03-27", "summary": "Align Technology (ALGN) recorded a Net Change in Cash of $51 million for the trailing twelve months (TTM) ended December 2025, and $90 million for the quarter ended December 2025. GuruFocus assesses ALGN with a GF Score of 89/100 and a GF Value of $249.91, indicating it is significantly undervalued compared to its current price of $166.38, despite having six warning signs for investors. The article details the calculation of Net Change in Cash and provides historical data and comparisons for the", "sentiment_score": 0.034708, "sentiment_label": "Neutral", "relevance_score": 0.562636, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Vanguard (HOLX) amendment shows 0 shares after Jan 12, 2026 realignment", "url": "https://www.stocktitan.net/sec-filings/HOLX/schedule-13g-a-hologic-inc-amended-passive-investment-disclosure-53cf00ba97e3.html", "date": "2026-03-27", "summary": "The Vanguard Group filed an amendment to its Schedule 13G/A, reporting 0 shares of Hologic Inc Common Stock. This change follows an internal realignment effective January 12, 2026, where certain Vanguard subsidiaries and business divisions will now report beneficial ownership separately, relying on SEC Release No. 34-39538. The filing confirms Vanguard directly holds 0 shares and 0% of the class, with no single outside person known to hold more than 5%.", "sentiment_score": 0.034678, "sentiment_label": "Neutral", "relevance_score": 0.315343, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Syquant Capital Sas Purchases New Stake in Hologic, Inc. $HOLX", "url": "https://www.marketbeat.com/instant-alerts/filing-syquant-capital-sas-purchases-new-stake-in-hologic-inc-holx-2026-03-27/", "date": "2026-03-27", "summary": "Syquant Capital Sas has acquired a new stake in Hologic, Inc. (HOLX) during the fourth quarter, purchasing 126,300 shares valued at approximately $9.41 million. This makes Hologic about 1.2% of Syquant's portfolio. Institutional ownership of Hologic is high at 94.73%, and while analysts generally issue a \"Hold\" rating with a consensus price target of $78.42, the company recently missed quarterly earnings and revenue estimates.", "sentiment_score": -0.20134, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "SG Americas Securities LLC Purchases 337,882 Shares of Hologic, Inc. $HOLX", "url": "https://www.marketbeat.com/instant-alerts/filing-sg-americas-securities-llc-purchases-337882-shares-of-hologic-inc-holx-2026-03-26/", "date": "2026-03-27", "summary": "SG Americas Securities LLC significantly increased its stake in Hologic, Inc. by 405.3% during the fourth quarter, purchasing 337,882 additional shares to hold a total of 421,240 shares valued at approximately $31.38 million. Despite this institutional buying, analyst sentiment for Hologic remains mixed, with an average \"Hold\" rating and a price target of $78.42, following recent downgrades and a slight earnings miss. The company's stock performance shows a 50-day moving average of $75.20 and a ", "sentiment_score": -0.143497, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.527, "confidence": 0.53 } }, { "source": "alpha_vantage", "title": "Pensionfund Sabic Takes $1.11 Million Position in Quest Diagnostics Incorporated $DGX", "url": "https://www.marketbeat.com/instant-alerts/filing-pensionfund-sabic-takes-111-million-position-in-quest-diagnostics-incorporated-dgx-2026-03-26/", "date": "2026-03-26", "summary": "Pensionfund Sabic initiated a new position in Quest Diagnostics (NYSE:DGX) in Q4, acquiring 6,400 shares valued at approximately $1.11 million. This move comes as Quest Diagnostics exceeded Q4 earnings expectations, announced a $1.0 billion share repurchase program, and raised its quarterly dividend. Analysts currently rate the stock with a consensus \"Moderate Buy\" and an average price target of $210.29.", "sentiment_score": 0.111759, "sentiment_label": "Neutral", "relevance_score": 0.610567, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Hologic stock sees fresh institutional interest as Pensionfund Sabic buys 18,800 shares amid medical", "url": "https://www.ad-hoc-news.de/boerse/ueberblick/hologic-stock-sees-fresh-institutional-interest-as-pensionfund-sabic-buys/68988633", "date": "2026-03-26", "summary": "Pensionfund Sabic recently acquired 18,800 shares of Hologic Inc (ISIN: US4364401012), signaling confidence in the women's health diagnostics leader. This move highlights the stock's appeal amid broader market rotations toward defensive healthcare plays, with Hologic specializing in women's health products like mammography systems and cervical cancer screening tools. The acquisition by a major Dutch pension fund suggests conviction in the company's long-term growth and stable returns, particular", "sentiment_score": 0.622305, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.758, "confidence": 0.76 } }, { "source": "alpha_vantage", "title": "Hologic stock sees fresh institutional interest as Pensionfund Sabic buys 18,800 shares amid medical", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/hologic-stock-sees-fresh-institutional-interest-as-pensionfund-sabic-buys/68988633", "date": "2026-03-26", "summary": "Pensionfund Sabic has acquired 18,800 shares of Hologic Inc., a women's health diagnostics leader, indicating institutional confidence in the company's long-term growth. This move highlights Hologic's appeal as a resilient medtech segment play, benefiting from predictable cash flows, high barriers to entry, and essential healthcare demand. The purchase aligns with a broader trend of pension funds seeking stable returns from companies like Hologic, which generate recurring revenue from consumable", "sentiment_score": 0.416571, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.758, "confidence": 0.76 } }, { "source": "alpha_vantage", "title": "18,800 Shares in Hologic, Inc. $HOLX Bought by Pensionfund Sabic", "url": "https://www.marketbeat.com/instant-alerts/filing-18800-shares-in-hologic-inc-holx-bought-by-pensionfund-sabic-2026-03-25/", "date": "2026-03-25", "summary": "Pensionfund Sabic recently bought 18,800 shares of Hologic, Inc. (NASDAQ:HOLX) for approximately $1.4 million in Q4, adding to significant institutional ownership which stands at 94.73%. Despite this, Hologic reported a Q4 earnings and revenue miss, affecting its stock performance. Analysts currently have a \"Hold\" rating on the stock with an average price target of $78.42.", "sentiment_score": 0.030066, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Therapy animals will reach 100,000 patients and care teams in pilot", "url": "https://www.stocktitan.net/news/BAX/pet-partners-and-the-baxter-foundation-expand-therapy-animal-h1e4g24dsxje.html", "date": "2026-03-25", "summary": "Pet Partners and the Baxter Foundation (NYSE: BAX) have launched a two-year pilot program to expand therapy animal visits, aiming to reach 100,000 patients and healthcare workers in three key U.S. regions. This initiative seeks to reduce stress and improve resilience by providing resources, training, and volunteer support, building on the proven benefits of human-animal interaction in healthcare settings. The program also includes research to further understand the impact of therapy animals on h", "sentiment_score": 0.218626, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.612387, "sentiment": { "label": "positive", "score": 0.511, "confidence": 0.51 } }, { "source": "alpha_vantage", "title": "Thermo Fisher completes $8.9B buyout of Clario", "url": "https://www.medtechdive.com/news/thermo-fisher-completes-89b-buyout-of-clario/815638/", "date": "2026-03-25", "summary": "Thermo Fisher Scientific has finalized its $8.9 billion acquisition of Clario, enhancing its capabilities in clinical trial endpoint data management. By integrating Clario's data capture and interpretation technology with its existing biological sample analysis, Thermo Fisher aims to create a unified, high-growth solution for drug developers. The deal, which includes potential earn-out payments, received approval from the European Commission with minimal competition concerns and is part of Therm", "sentiment_score": 0.104919, "sentiment_label": "Neutral", "relevance_score": 0.607876, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "HOLX or ALGN: Which Medical Technology Stock Should You Choose for Investment Right Now?", "url": "https://www.bitget.com/amp/news/detail/12560605303579", "date": "2026-03-25", "summary": "This article compares two prominent medical technology companies, Hologic (HOLX) and Align Technology (ALGN), for investment potential. While Hologic's diagnostics segment faces challenges and a pending privatization deal offers minimal upside, Align Technology demonstrates strong growth in its clear aligner business with positive analyst sentiment and an attractive valuation, suggesting it's the more favorable investment.", "sentiment_score": -0.429388, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "HOLX vs. ALGN: Which MedTech Stock Is the Better Investment Pick Now?", "url": "https://www.tradingview.com/news/zacks:08917ea12094b:0-holx-vs-algn-which-medtech-stock-is-the-better-investment-pick-now/", "date": "2026-03-25", "summary": "This article provides a comparative analysis of two MedTech companies, Hologic (HOLX) and Align Technology (ALGN), discussing their market positions, recent performance, and future prospects. It concludes that Align Technology is a better investment due to strong Clear Aligner volume growth, strategic progress with DSOs, and positive analyst sentiment, while Hologic's limited upside from its buyout deal and declining COVID testing sales make it a less attractive option for current shareholders.", "sentiment_score": 0.068655, "sentiment_label": "Neutral", "relevance_score": 0.929297, "sentiment": { "label": "positive", "score": 0.44, "confidence": 0.44 } }, { "source": "alpha_vantage", "title": "Hologic upgraded at Evercore ISI on growth turnaround", "url": "http://www.msn.com/en-us/money/markets/hologic-upgraded-at-evercore-isi-on-growth-turnaround/ar-AA1O1Kj2?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "date": "2026-03-22", "summary": "Evercore ISI upgraded Hologic's stock rating, citing expectations for a growth turnaround and an improved financial outlook for the company. This positive outlook from the analytical firm suggests confidence in Hologic's future performance.", "sentiment_score": 0.420454, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.582, "confidence": 0.58 } }, { "source": "alpha_vantage", "title": "Investors heavily search Hologic, Inc. (HOLX): Here is what you need to know", "url": "https://www.msn.com/en-us/money/topstocks/investors-heavily-search-hologic-inc-holx-here-is-what-you-need-to-know/ar-AA1Z40cO", "date": "2026-03-20", "summary": "This article identifies Hologic, Inc. (HOLX) as a highly searched stock, indicating significant investor interest. It suggests that investors are looking for key information about the company. The content provided is minimal, only stating \"MSN\" which implies the article was scraped from the MSN platform.", "sentiment_score": 0.008625, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Investors Are Actively Looking Into Hologic, Inc. (HOLX): What You Should Be Aware Of", "url": "https://www.bitget.com/amp/news/detail/12560605285890", "date": "2026-03-20", "summary": "Hologic (HOLX) is gaining investor attention, with a modest 0.3% share increase over the past month, contrasting with declines in the broader market and its sector. Earnings projections show anticipated growth for current and next fiscal years, but the company currently holds a Zacks Rank #4 (Sell) due to recent earnings estimate revisions. While revenue growth is forecast, recent performance saw revenues and EPS slightly below consensus estimates, and its valuation is in line with industry peer", "sentiment_score": -0.214082, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.318, "confidence": 0.32 } }, { "source": "alpha_vantage", "title": "Investors Are Actively Looking Into Hologic, Inc. (HOLX): What You Should Be Aware Of", "url": "https://www.bitget.com/asia/news/detail/12560605285890", "date": "2026-03-20", "summary": "Hologic, Inc. (HOLX) has seen increased investor attention, with shares experiencing a modest 0.3% increase over the past month, contrasting with broader market declines. Despite some positive earnings estimate revisions, the company currently holds a Zacks Rank #4 (Sell), suggesting it may underperform the market. Investors are advised to consider fundamental factors like earnings and revenue growth, along with valuation insights, to assess Hologic's future prospects.", "sentiment_score": -0.225792, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.318, "confidence": 0.32 } }, { "source": "alpha_vantage", "title": "Investors Are Actively Looking Into Hologic, Inc. (HOLX): What You Should Be Aware Of", "url": "https://www.bitget.com/news/detail/12560605285890", "date": "2026-03-20", "summary": "Hologic (HOLX) has garnered investor attention, with its shares showing a modest 0.3% increase over the past month, contrasting with broader market and sector declines. Despite positive revenue growth forecasts and past earnings beats, the company currently holds a Zacks Rank #4 (Sell) due to recent earnings estimate revisions and other factors, suggesting a less favorable near-term outlook. Investors are encouraged to consider fundamental factors like earnings and revenue trends, and valuation ", "sentiment_score": -0.23318, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.318, "confidence": 0.32 } }, { "source": "alpha_vantage", "title": "Hologic's Women's Health Index Flags Alarming Gaps in STI Screening", "url": "https://sg.finance.yahoo.com/news/hologics-womens-health-index-flags-131200905.html", "date": "2026-03-19", "summary": "Hologic's Global Women's Health Index, an annual survey, has revealed a persistent screening gap for sexually transmitted infections (STIs), with only 10% of women reporting testing in the past year, a figure unchanged over five years. This alarming statistic puts nearly 2 billion women at risk of serious health consequences. Despite improvements in screening for other conditions like high blood pressure, cancer, and diabetes, STI testing remains a critical unmet need, even as Hologic offers mol", "sentiment_score": 0.146738, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.128, "confidence": 0.13 } }, { "source": "alpha_vantage", "title": "Hologic's Women's Health Index Flags Alarming Gaps in STI Screening", "url": "https://finance.yahoo.com/sectors/healthcare/articles/hologics-womens-health-index-flags-131200905.html", "date": "2026-03-19", "summary": "Hologic's latest Global Women’s Health Index, developed with Gallup, reveals a persistent gap in STI screening globally, with only 10% of women reporting testing in the past year—a figure unchanged since the Index's inception. While screening rates for conditions like high blood pressure, cancer, and diabetes have improved, the lack of progress in STI testing leaves nearly 2 billion women at risk of serious health consequences. The article also touches upon Hologic's molecular diagnostic assays ", "sentiment_score": 0.135035, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.128, "confidence": 0.13 } }, { "source": "alpha_vantage", "title": "Is Hologic Stock Outperforming the Dow?", "url": "https://www.barchart.com/story/news/820477/is-hologic-stock-outperforming-the-dow", "date": "2026-03-18", "summary": "Hologic, Inc. (HOLX) has outperformed the Dow Jones Industrials Average ($DOWI) over the past three months, year-to-date, and over the past 52 weeks, despite a recent dip after Q1 2026 results. The company's stock has risen marginally in these periods while the Dow has seen decreases or lesser returns. Analysts, however, maintain a \"Hold\" rating on HOLX with a mean price target suggesting only a marginal premium.", "sentiment_score": -0.088941, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "Should You Hold or Sell HOLX Stock as It Nears the End of Public Phase?", "url": "https://www.tradingview.com/news/zacks:c8d1909fd094b:0-should-you-hold-or-sell-holx-stock-as-it-nears-the-end-of-public-phase/", "date": "2026-03-18", "summary": "Hologic (HOLX) is nearing the completion of its take-private deal by Blackstone and TPG at $76 per share, plus a potential $3 CVR. While the company's Q1 fiscal 2026 results showed weaknesses in Diagnostics, particularly due to declining COVID-19 and STI test sales, its Breast Health and GYN Surgical divisions performed well. Given that HOLX stock is trading close to the buyout price and its valuation is stretched compared to peers, investors are advised to consider exiting their positions.", "sentiment_score": -0.209851, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Hologic, Inc. $HOLX Shares Sold by Alliancebernstein L.P.", "url": "https://www.marketbeat.com/instant-alerts/filing-hologic-inc-holx-shares-sold-by-alliancebernstein-lp-2026-03-17/", "date": "2026-03-18", "summary": "Alliancebernstein L.P. trimmed its holdings in Hologic, Inc. (NASDAQ:HOLX) by 6.4% in the third quarter, selling 144,403 shares. Despite this, other institutions like The Manufacturers Life Insurance Company and Invesco Ltd. significantly increased their stakes, bringing institutional ownership to 94.73%. Hologic recently reported an EPS miss and revenue of $1.05 billion, trading near its 52-week high with a consensus analyst rating of \"Hold.\"", "sentiment_score": -0.141979, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Mammography Devices Market Poised for Robust Growth at 8.25%", "url": "https://www.openpr.com/news/4428671/mammography-devices-market-poised-for-robust-growth-at-8-25", "date": "2026-03-18", "summary": "The global mammography devices market is projected to reach USD 5,427.49 million by 2034, growing at a CAGR of 8.25% from 2026 to 2034. This growth is driven by increasing breast cancer incidence, a focus on early detection, and the adoption of advanced imaging technologies. North America is expected to lead the market, while digital mammography devices, particularly Full-Field Digital Mammography (FFDM), dominate the device types.", "sentiment_score": 0.422672, "sentiment_label": "Bullish", "relevance_score": 0.937345, "sentiment": { "label": "positive", "score": 0.718, "confidence": 0.72 } }, { "source": "alpha_vantage", "title": "Hercules Capital (NYSE:HTGC) - Stock Analysis", "url": "https://simplywall.st/stocks/us/diversified-financials/nyse-htgc/hercules-capital", "date": "2026-03-17", "summary": "This Simply Wall St analysis provides an overview of Hercules Capital (NYSE:HTGC), a business development company specializing in venture debt and growth capital. The report details the company's valuation, growth prospects, past performance, financial health, and dividend information, highlighting that the stock is trading below its fair value with expected earnings growth. It also presents various analyst and community narratives on its future potential and risks, along with historical price p", "sentiment_score": 0.222438, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.613888, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "1.5 Billion Women Miss Essential Preventive Tests, Despite Uptick in Global Screening Rates", "url": "https://www.businesswire.com/news/home/20260317786907/en/1.5-Billion-Women-Miss-Essential-Preventive-Tests-Despite-Uptick-in-Global-Screening-Rates", "date": "2026-03-17", "summary": "The fifth edition of the Hologic Global Women's Health Index, in partnership with Gallup, reveals that 1.5 billion women globally are missing essential preventive health screenings for conditions like cancer, high blood pressure, diabetes, and STIs. While there's been a slight increase in some screening rates, overall progress is limited, and the global women’s health score remains unchanged from five years ago. The report calls for expanding access to early detection and developing national wom", "sentiment_score": 0.141883, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.153, "confidence": 0.15 } }, { "source": "alpha_vantage", "title": "1.5 Billion Women Miss Essential Preventive Tests, Despite Uptick in Global Screening Rates", "url": "https://investors.hologic.com/press-releases/press-release-details/2026/1-5-Billion-Women-Miss-Essential-Preventive-Tests-Despite-Uptick-in-Global-Screening-Rates/default.aspx", "date": "2026-03-17", "summary": "A new report from Hologic, Inc. and Gallup reveals that 1.5 billion women worldwide are missing essential preventive health screenings for conditions like cancer, high blood pressure, diabetes, and STIs, despite slight increases in global screening rates for some conditions. The fifth edition of the Hologic Global Women’s Health Index indicates that overall global women's health has not improved over the past five years, with high levels of physical pain, worry, and sadness reported, and many wo", "sentiment_score": 0.260393, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.153, "confidence": 0.15 } }, { "source": "alpha_vantage", "title": "Brevan Howard Capital Management LP Increases Position in Hologic, Inc. $HOLX", "url": "https://www.marketbeat.com/instant-alerts/filing-brevan-howard-capital-management-lp-increases-position-in-hologic-inc-holx-2026-03-17/", "date": "2026-03-17", "summary": "Brevan Howard Capital Management LP significantly increased its stake in Hologic, Inc. (NASDAQ:HOLX) by 163.6% in the third quarter, acquiring an additional 29,009 shares to reach a total of 46,737 shares valued at $3.15 million. Other institutional investors like Cinctive Capital Management LP and Bank of Nova Scotia also boosted their holdings, contributing to Hologic's 94.73% institutional ownership. Despite this increased institutional interest, analyst sentiment in Hologic has cooled to a \"", "sentiment_score": -0.245587, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Sectra acquiring Oxipit | RadNet's $300M in 2026 acquisitions | Hologic clears hurdle in $18B sale to PE | More", "url": "https://radiologybusiness.com/newsletter/2026-03-16/sectra-acquiring-oxipit-radnets-300m-2026-acquisitions-hologic-clears-hurdle-18b-sale-pe-more", "date": "2026-03-16", "summary": "This article summarizes recent merger and acquisition activities in the radiology and medical imaging sector. Key deals include Sectra's acquisition of Oxipit, RadNet's significant investments in 2026 through the acquisition of AI firm Gleamer and several imaging centers, and Hologic's proposed $18B sale to private equity firms TPG and Blackstone. Additionally, Quantum Surgical acquired NeuWave Medical, and RadNet expanded its footprint by acquiring Chesapeake Medical Imaging, Cimar UK, and Nort", "sentiment_score": 0.327022, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.801301, "sentiment": { "label": "positive", "score": 0.277, "confidence": 0.28 } }, { "source": "alpha_vantage", "title": "Technical Reactions to HOLX Trends in Macro Strategies", "url": "https://news.stocktradersdaily.com/news_release/91/Technical_Reactions_to_HOLX_Trends_in_Macro_Strategies_031626031601_1773688562.html", "date": "2026-03-16", "summary": "This article provides a technical analysis of Hologic Inc. (NASDAQ: HOLX), highlighting neutral near and mid-term readings that could moderate its long-term positive bias. It identifies key support and resistance levels and offers exceptional risk-reward setups for potential gains. The analysis includes AI-generated institutional trading strategies tailored to various risk profiles.", "sentiment_score": 0.029636, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "HOLX Stock Gains on FDA & CE Approval for Automated Molecular GI Tests", "url": "http://www.msn.com/en-us/health/other/holx-stock-gains-on-fda-ce-approval-for-automated-molecular-gi-tests/ar-AA1NNSY9?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "date": "2026-03-16", "summary": "Hologic, Inc. (HOLX) stock rose after receiving FDA clearance and CE Mark for its Novodiag assays, designed for automated molecular detection of gastrointestinal infections. These tests run on the Novodiag system and offer rapid, on-demand results, expanding Hologic's diagnostics portfolio and potentially improving patient care. The approval is expected to strengthen the company's competitive position in the diagnostics market.", "sentiment_score": 0.416876, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.67, "confidence": 0.67 } }, { "source": "alpha_vantage", "title": "Earnest Partners LLC Purchases 26,877 Shares of Hologic, Inc. $HOLX", "url": "https://www.marketbeat.com/instant-alerts/filing-earnest-partners-llc-purchases-26877-shares-of-hologic-inc-holx-2026-03-15/", "date": "2026-03-15", "summary": "Earnest Partners LLC increased its stake in Hologic, Inc. (NASDAQ:HOLX) by 1.4% in the third quarter, acquiring an additional 26,877 shares to bring their total holding to 1,911,191 shares valued at approximately $128.99 million. This move comes as institutional ownership in Hologic is notably high at 94.73%, despite the company recently missing quarterly earnings and revenue estimates. Analysts currently maintain a \"Hold\" rating for Hologic with a consensus price target of $78.42.", "sentiment_score": -0.194377, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.67, "confidence": 0.67 } }, { "source": "alpha_vantage", "title": "Why Hologic Just Hit Your Health And Money Feeds At Once", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/why-hologic-just-hit-your-health-and-money-feeds-at-once/68669582", "date": "2026-03-13", "summary": "Hologic, Inc. (HOLX) is a medical technology company focused on women's health, diagnostics, and surgical products, significantly impacting early cancer detection and STI testing in the US. While not a consumer-facing brand, its technology is widely used in mammography, Pap tests, and infectious disease diagnostics. The company's stock is drawing investor attention as it navigates the post-pandemic landscape, relying on a rebound in screening volumes, a strong innovation pipeline, and its stable", "sentiment_score": 0.538062, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Nephros (NASDAQ: NEPH) extends Medica deal and outlines major business risks", "url": "https://www.stocktitan.net/sec-filings/NEPH/10-k-nephros-inc-files-annual-report-dd13948c5030.html", "date": "2026-03-12", "summary": "Nephros (NASDAQ: NEPH) has filed its annual report, detailing its profitable water-filtration business with a focus on medical-grade and commercial solutions. The company reported profitability in 2024 and 2025 despite a significant accumulated deficit and dependence on a few key customers and suppliers. A renewed agreement with Medica extends their exclusive supply deal through 2030 with increasing minimum purchase commitments, while the company also highlighted a material weakness in revenue r", "sentiment_score": 0.072074, "sentiment_label": "Neutral", "relevance_score": 0.602834, "sentiment": { "label": "negative", "score": -0.221, "confidence": 0.22 } }, { "source": "alpha_vantage", "title": "Mackenzie Financial Corp Sells 141,733 Shares of Hologic, Inc. $HOLX", "url": "https://www.marketbeat.com/instant-alerts/filing-mackenzie-financial-corp-sells-141733-shares-of-hologic-inc-holx-2026-03-12/", "date": "2026-03-12", "summary": "Mackenzie Financial Corp reduced its stake in Hologic, Inc. by 12.1% in the third quarter, selling 141,733 shares. Despite this, other institutions significantly increased their holdings, with institutional investors now owning approximately 94.73% of the company. Hologic recently missed quarterly earnings and revenue estimates and holds an average \"Hold\" rating from analysts with a consensus price target of $78.42.", "sentiment_score": -0.242371, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Short Interest in Hologic, Inc. (NASDAQ:HOLX) Grows By 71.7%", "url": "https://www.marketbeat.com/instant-alerts/short-interest-in-hologic-inc-nasdaqholx-grows-by-717-2026-03-13/", "date": "2026-03-11", "summary": "Short interest in Hologic, Inc. (NASDAQ:HOLX) surged by 71.7% in February, reaching 8,301,510 shares, representing 3.8% of the stock and a 3.8 days-to-cover ratio. Despite significant institutional ownership at 94.73%, analysts maintain a cautious \"Hold\" rating with a consensus price target of $78.42. This increase in short interest follows Hologic missing its quarterly EPS and revenue estimates.", "sentiment_score": -0.239959, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.459, "confidence": 0.46 } }, { "source": "alpha_vantage", "title": "Korea Investment CORP Has $2.66 Million Stake in Hologic, Inc. $HOLX", "url": "https://www.marketbeat.com/instant-alerts/filing-korea-investment-corp-has-266-million-stake-in-hologic-inc-holx-2026-03-13/", "date": "2026-03-11", "summary": "Korea Investment CORP significantly reduced its stake in Hologic, Inc. by 50% in the third quarter, selling 39,500 shares and retaining 39,431 shares valued at $2.661 million. Meanwhile, other institutional investors like The Manufacturers Life Insurance Company and Invesco Ltd. substantially increased their holdings in Hologic. The company's recent earnings report showed an EPS of $1.04, missing estimates, and revenue of $1.05 billion, below expectations, leading analysts to maintain a consensu", "sentiment_score": -0.215298, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Citigroup Increases Johnson & Johnson (NYSE:JNJ) Price Target to $274.00", "url": "https://www.marketbeat.com/instant-alerts/citigroup-increases-johnson-johnson-nysejnj-price-target-to-27400-2026-03-11/", "date": "2026-03-11", "summary": "Citigroup has raised its price target for Johnson & Johnson (NYSE:JNJ) to $274.00 from $250.00, reiterating a \"buy\" rating due to recent regulatory approvals for key oncology drugs and an EU label expansion. While these developments bolster J&J's growth prospects, the stock also faces potential downside volatility from increased short interest and insider selling. Other analysts have a \"Moderate Buy\" consensus for JNJ with an average target price of $235.91.", "sentiment_score": 0.054358, "sentiment_label": "Neutral", "relevance_score": 0.58678, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Sexually Transmitted Disease Testing Market size to exceed $23.91 Billion by 2035 | Abbott Laboratories, Roche Diagnostics, Hologic Inc, Becton, Dickinson and Company (BD), Thermo Fisher Scientific", "url": "https://www.openpr.com/news/4420709/sexually-transmitted-disease-testing-market-size-to-exceed", "date": "2026-03-11", "summary": "The Sexually Transmitted Disease Testing Market is projected to grow from an estimated $10.77 billion in 2025 to $23.91 billion by 2035, driven by technological advancements, increased healthcare access, and public health campaigns. North America is expected to experience the fastest growth, while the Asia Pacific region is anticipated to hold the largest market share by the end of 2035. Key trends include the rapid expansion of at-home STD testing, adoption of molecular diagnostic technologies,", "sentiment_score": 0.339228, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.994866, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Natixis Advisors LLC Acquires 82,894 Shares of Hologic, Inc. $HOLX", "url": "https://www.marketbeat.com/instant-alerts/filing-natixis-advisors-llc-acquires-82894-shares-of-hologic-inc-holx-2026-03-11/", "date": "2026-03-11", "summary": "Natixis Advisors LLC has increased its stake in Hologic, Inc. (NASDAQ:HOLX) by 23.4%, acquiring an additional 82,894 shares to hold a total of 437,338 shares valued at approximately $29.52 million. This increase occurred despite Hologic missing its quarterly earnings and revenue expectations, reporting $1.04 EPS versus $1.09 expected and $1.05 billion in revenue against an anticipated $1.07 billion. Analysts currently maintain a consensus \"Hold\" rating for Hologic with a target price of $78.42.", "sentiment_score": -0.212277, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "What Drives Hologic's GYN Surgical Strength in a Competitive Market?", "url": "https://www.theglobeandmail.com/investing/markets/stocks/JNJ/pressreleases/665414/what-drives-hologics-gyn-surgical-strength-in-a-competitive-market/", "date": "2026-03-10", "summary": "Hologic, a key player in the global women's health devices market, maintains its strength in GYN Surgical despite competition from Medtronic and Johnson & Johnson. Its consistent performance is attributed to internal product development, strategic acquisitions like Gynesonics and Acessa, and expanding international market reach for minimally invasive gynecological treatments. The company's financials show a 20.7% share price rise and a Zacks Rank #4 (Sell), with a P/S ratio reflecting its valuat", "sentiment_score": 0.230072, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.599, "confidence": 0.6 } }, { "source": "alpha_vantage", "title": "Microplate Systems Market Is Going to Boom |• Thermo Fisher Scientific • Agilent Technologies", "url": "https://www.openpr.com/news/4418875/microplate-systems-market-is-going-to-boom-thermo-fisher", "date": "2026-03-10", "summary": "Worldwide Market Reports has released a comprehensive research study on the Microplate Systems market, forecasting its growth from 2026 to 2033. The report analyzes key market drivers, challenges, opportunities, and restraints, providing insights into the competitive landscape and regional trends. It highlights leading players like Thermo Fisher Scientific and Agilent Technologies, segmenting the market by types and applications.", "sentiment_score": 0.30068, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.626892, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Dimensional Fund Advisors LP Has $155.75 Million Position in Hologic, Inc. $HOLX", "url": "https://www.marketbeat.com/instant-alerts/filing-dimensional-fund-advisors-lp-has-15575-million-position-in-hologic-inc-holx-2026-03-10/", "date": "2026-03-10", "summary": "Dimensional Fund Advisors LP trimmed its stake in Hologic, Inc. by 8.4% during Q3, now holding 2.3 million shares valued at approximately $155.75 million. This adjustment comes as Hologic recently missed analyst estimates for EPS and revenue, though the stock trades near its 1-year high. Analysts generally rate HOLX as a \"Hold,\" with an average target price of $78.42.", "sentiment_score": 0.001648, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "What Drives Hologic's GYN Surgical Strength in a Competitive Market?", "url": "https://finance.yahoo.com/news/drives-hologics-gyn-surgical-strength-123700146.html", "date": "2026-03-10", "summary": "Hologic, a key player in the global women's health devices market, maintains a strong position in GYN Surgical despite competitive pressure from giants like Medtronic and Johnson & Johnson. The company's GYN Surgical unit, bolstered by strategic acquisitions and internal product development, consistently shows growth, driven by increasing awareness of gynecological disorders and demand for minimally invasive solutions. While Hologic continues to expand its international market share, its stock p", "sentiment_score": 0.320085, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.599, "confidence": 0.6 } }, { "source": "alpha_vantage", "title": "Here’s What You Should Understand Besides Why Hologic, Inc. (HOLX) is Gaining Attention", "url": "https://www.bitget.com/amp/news/detail/12560605249678", "date": "2026-03-10", "summary": "Hologic (HOLX) has seen a 1.2% stock price increase in the past month, outperforming the S&P 500 and its sector. Analysts project earnings growth for the current and next fiscal years, with revenue also expected to rise. Despite recent positive momentum, Hologic holds a Zacks Rank #4 (Sell), suggesting potential near-term underperformance.", "sentiment_score": 0.090177, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.421, "confidence": 0.42 } }, { "source": "alpha_vantage", "title": "Hologic, Inc. $HOLX Shares Bought by Crossmark Global Holdings Inc.", "url": "https://www.marketbeat.com/instant-alerts/filing-hologic-inc-holx-shares-bought-by-crossmark-global-holdings-inc-2026-03-09/", "date": "2026-03-09", "summary": "Crossmark Global Holdings Inc. significantly increased its stake in Hologic, Inc. (HOLX) by 107.1% in the third quarter, bringing their total holdings to 32,207 shares. Despite Hologic missing its quarterly EPS and revenue estimates, institutional investors now own 94.73% of the company. Analysts maintain a \"Hold\" rating for Hologic, with an average price target of $78.42, even as the stock trades near its 52-week high.", "sentiment_score": 0.070736, "sentiment_label": "Neutral", "relevance_score": 0.963196, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Here is What to Know Beyond Why Hologic, Inc. (HOLX) is a Trending Stock", "url": "https://www.sharewise.com/us/news_articles/Here_is_What_to_Know_Beyond_Why_Hologic_Inc_HOLX_is_a_Trending_Stock_Zacks_20260309_1400", "date": "2026-03-09", "summary": "This article examines Hologic, Inc. (HOLX), a medical device maker, which has been a trending stock on Zacks.com. It delves into crucial factors influencing its near-term performance such as earnings estimate revisions, revenue growth forecasts, and valuation. Despite generating market buzz, the company holds a Zacks Rank #4 (Sell), suggesting potential underperformance.", "sentiment_score": -0.215723, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41902238", "title": "Whole-Genome Phylodynamic Analysis of Respiratory Syncytial Virus-Maryland, USA, 2018-2024.", "authors": "Zhuang TX et al.", "journal": "Viruses", "date": "2026 Mar 7", "url": "https://pubmed.ncbi.nlm.nih.gov/41902238/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41885612", "title": "Comparison of Respiratory Syncytial Virus (RSV)-Specific Antibody Durability in Pregnant/Postpartum Individuals and Older Adults After RSV Vaccination.", "authors": "Kachikis A et al.", "journal": "The Journal of infectious diseases", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41885612/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41885439", "title": "Positive nucleic acid amplification test results are rarely indicative of a viable rectal Chlamydia trachomatis infection among men with anal exposures other than receptive anal sex.", "authors": "Khosropour CM et al.", "journal": "Sexually transmitted diseases", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41885439/", "sentiment": { "label": "positive", "score": 0.557, "confidence": 0.56 } }, { "source": "pubmed", "pmid": "41878523", "title": "Dual-modality CAD for breast cancer screening: dealing with discordant diagnosis between mammography and tomography.", "authors": "Beaumont H et al.", "journal": "Frontiers in oncology", "date": "2026-03-30", "url": "https://pubmed.ncbi.nlm.nih.gov/41878523/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41874876", "title": "Recent Trends in Whole-Breast Irradiation Versus Partial-Breast Irradiation in Ductal Carcinoma in situ with Breast-Conserving Surgery 2011-2021: A National Cancer Database Study.", "authors": "Jeng A et al.", "journal": "Annals of surgical oncology", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41874876/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41874107", "title": "Estimating the sensitivity of non-treponemal and treponemal antibody tests in primary syphilis.", "authors": "Sweitzer SF et al.", "journal": "Sexually transmitted diseases", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41874107/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41861507", "title": "Reinfection following direct-acting antiviral therapy for hepatitis C infection among people in prison with recent injecting drug use: the SHARP-P study.", "authors": "Conway A et al.", "journal": "The International journal on drug policy", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41861507/", "sentiment": { "label": "negative", "score": -0.511, "confidence": 0.51 } }, { "source": "pubmed", "pmid": "41858853", "title": "Sex and age specific bone mineral density trends in Sri Lankan adults support the need for normative reference data.", "authors": "Varatharajan M et al.", "journal": "Frontiers in endocrinology", "date": "2026-03-30", "url": "https://pubmed.ncbi.nlm.nih.gov/41858853/", "sentiment": { "label": "positive", "score": 0.402, "confidence": 0.4 } }, { "source": "pubmed", "pmid": "41858246", "title": "Unsatisfactory ThinPrep Pap Tests: An Educational Approach to Quality.", "authors": "Olson K et al.", "journal": "Diagnostic cytopathology", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41858246/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41856415", "title": "BlotDx: A deep learning tool for Western blot-based diagnostics.", "authors": "Liu L et al.", "journal": "Journal of virological methods", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41856415/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41849329", "title": "Association between vaginal washing and group B Streptococcus colonization from periconception through the first trimester of pregnancy in a cohort of Kenyan women.", "authors": "Jisuvei CS et al.", "journal": "PloS one", "date": "2026-03-30", "url": "https://pubmed.ncbi.nlm.nih.gov/41849329/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41848413", "title": "Factors Associated With Opioid Agonist Treatment Engagement and Harm Reduction Service Use: Findings From the New South Wales Opioid Dependence Survey.", "authors": "Santo T Jr et al.", "journal": "Drug and alcohol review", "date": "2026-03-30", "url": "https://pubmed.ncbi.nlm.nih.gov/41848413/", "sentiment": { "label": "negative", "score": -0.128, "confidence": 0.13 } }, { "source": "pubmed", "pmid": "41825191", "title": "2023-2024 COVID-19 vaccination coverage in pregnancy in ten healthcare delivery organizations in the United States.", "authors": "Irving SA et al.", "journal": "Vaccine", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41825191/", "sentiment": { "label": "positive", "score": 0.421, "confidence": 0.42 } }, { "source": "pubmed", "pmid": "41820630", "title": "Predictive value of BMD for hip and other fractures: a meta-analysis to update FRAX.", "authors": "Kanis JA et al.", "journal": "Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41820630/", "sentiment": { "label": "positive", "score": 0.34, "confidence": 0.34 } }, { "source": "pubmed", "pmid": "41820501", "title": "Clinical performance of ASCL1/LHX8 DNA methylation on first-void urine to screen for cervical cancer.", "authors": "Van Keer S et al.", "journal": "Communications medicine", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41820501/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41818161", "title": "Interim Estimates of 2025-26 Seasonal Influenza Vaccine Effectiveness - United States, September 2025-February 2026.", "authors": "Maloney P et al.", "journal": "MMWR. Morbidity and mortality weekly report", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41818161/", "sentiment": { "label": "positive", "score": 0.421, "confidence": 0.42 } }, { "source": "pubmed", "pmid": "41817930", "title": "ASO Visual Abstract: Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer-Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study.", "authors": "Kuemmel S et al.", "journal": "Annals of surgical oncology", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41817930/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41809918", "title": "Compliance of Dermatology Screening Visits Among Patients With Skin Cancer-Predisposing Pathogenic Variants.", "authors": "Gadomski SJ et al.", "journal": "JEADV clinical practice", "date": "2026-03-30", "url": "https://pubmed.ncbi.nlm.nih.gov/41809918/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41806477", "title": "A 3D-printed anthropomorphic breast phantom with realistic anatomy and attenuation properties for spatially resolved dosimetry in mammography.", "authors": "Liu Y et al.", "journal": "Physics in medicine and biology", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41806477/", "sentiment": { "label": "positive", "score": 0.178, "confidence": 0.18 } }, { "source": "pubmed", "pmid": "41806049", "title": "Task-Based Sampling of Patient Data for Rigorous Machine Learning/AI Performance Assessment.", "authors": "Baughan N et al.", "journal": "Journal of imaging informatics in medicine", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41806049/", "sentiment": { "label": "negative", "score": -0.273, "confidence": 0.27 } }, { "source": "pubmed", "pmid": "41801760", "title": "Vaccine-Elicited Antibody Responses to Influenza A(H3N2) Subclade K.", "authors": "Wang L et al.", "journal": "JAMA", "date": "2026 Mar 9", "url": "https://pubmed.ncbi.nlm.nih.gov/41801760/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41786830", "title": "Metagenomic analysis reveals rectal microbiota features associated with HIV and behavioral factors in Nigerian men who have sex with men.", "authors": "Nowak RG et al.", "journal": "Scientific reports", "date": "2026 Mar 5", "url": "https://pubmed.ncbi.nlm.nih.gov/41786830/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41781728", "title": "Finding the optimal recall rate in breast cancer screening: results from the ROCS study.", "authors": "van der Waal D et al.", "journal": "European radiology", "date": "2026 Mar 5", "url": "https://pubmed.ncbi.nlm.nih.gov/41781728/", "sentiment": { "label": "negative", "score": -0.64, "confidence": 0.64 } }, { "source": "pubmed", "pmid": "41780548", "title": "Digital breast tomosynthesis and reading with artificial intelligence.", "authors": "Weigel S et al.", "journal": "RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin", "date": "2026 Mar 4", "url": "https://pubmed.ncbi.nlm.nih.gov/41780548/", "sentiment": { "label": "positive", "score": 0.477, "confidence": 0.48 } }, { "source": "pubmed", "pmid": "41779026", "title": "A meta-analysis of smoking and fracture risk to update the FRAX® tool.", "authors": "Schini M et al.", "journal": "Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA", "date": "2026 Mar 4", "url": "https://pubmed.ncbi.nlm.nih.gov/41779026/", "sentiment": { "label": "negative", "score": -0.273, "confidence": 0.27 } }, { "source": "pubmed", "pmid": "41774047", "title": "Ductal Carcinoma In Situ Active Monitoring Trials: Do Eligibility Criteria Identify Patients at Low Risk for Upgrade to Invasive Carcinoma?", "authors": "Ataya DK et al.", "journal": "Journal of breast imaging", "date": "2026 Mar 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41774047/", "sentiment": { "label": "positive", "score": 0.072, "confidence": 0.07 } }, { "source": "pubmed", "pmid": "41772223", "title": "Handing off hope: transition of care in pediatric surgery.", "authors": "Wunker CM et al.", "journal": "Surgical endoscopy", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41772223/", "sentiment": { "label": "positive", "score": 0.727, "confidence": 0.73 } }, { "source": "pubmed", "pmid": "41734278", "title": "RUMINA: high-throughput deduplication of unique molecular identifiers for amplicon and whole-genome sequencing with enhanced error correction.", "authors": "Piliper E et al.", "journal": "Bioinformatics (Oxford, England)", "date": "2026 Feb 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41734278/", "sentiment": { "label": "negative", "score": -0.402, "confidence": 0.4 } }, { "source": "pubmed", "pmid": "41722159", "title": "Comparison between RT-PCR and TMA for SARS-CoV-2 detection and proposal of a diagnostic algorithm based on cut-off values.", "authors": "Bernet Sánchez A et al.", "journal": "Enfermedades infecciosas y microbiologia clinica (English ed.)", "date": "2026-03-30", "url": "https://pubmed.ncbi.nlm.nih.gov/41722159/", "sentiment": { "label": "positive", "score": 0.402, "confidence": 0.4 } }, { "source": "pubmed", "pmid": "41708869", "title": "Ancestry and somatic profile indicate acral melanoma origin and prognosis.", "authors": "Basurto-Lozada P et al.", "journal": "Nature", "date": "2026-03-30", "url": "https://pubmed.ncbi.nlm.nih.gov/41708869/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41704424", "title": "Compression pressure of the external jugular vein for the assessment of intravascular volume status in decompensated cirrhosis: A pilot study.", "authors": "Segna D et al.", "journal": "JHEP reports : innovation in hepatology", "date": "2026-03-30", "url": "https://pubmed.ncbi.nlm.nih.gov/41704424/", "sentiment": { "label": "negative", "score": -0.296, "confidence": 0.3 } }, { "source": "pubmed", "pmid": "41666011", "title": "Developing Advocacy Skills in Breast Radiologists.", "authors": "Elahi F et al.", "journal": "Journal of breast imaging", "date": "2026 Mar 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41666011/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41661663", "title": "Contrast-Enhanced Mammography-Guided Biopsy for MRI-Detected Breast Lesions: A Prospective Study.", "authors": "Cao Y et al.", "journal": "Journal of breast imaging", "date": "2026 Mar 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41661663/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41661649", "title": "Prevalence of Acute and Delayed Contrast Reactions With Multiple Exposures to Contrast-Enhanced Mammography-Experience From the TOCEM Trial.", "authors": "Gu L et al.", "journal": "Journal of breast imaging", "date": "2026 Mar 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41661649/", "sentiment": { "label": "negative", "score": -0.226, "confidence": 0.23 } }, { "source": "pubmed", "pmid": "41589842", "title": "Emergence of influenza A(H3N2) subclade K in northeast Ohio in autumn 2025.", "authors": "Xu X et al.", "journal": "Journal of clinical microbiology", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41589842/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41588113", "title": "TORC1-dependent translation drives chromatin remodeling during the germ-cell-to-maternal transition in Drosophila.", "authors": "Kotb NM et al.", "journal": "The EMBO journal", "date": "2026-03-30", "url": "https://pubmed.ncbi.nlm.nih.gov/41588113/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41561732", "title": "Association between knee osteoarthritis and volumetric bone mineral density.", "authors": "Hoang DK et al.", "journal": "Osteoarthritis and cartilage open", "date": "2026-03-30", "url": "https://pubmed.ncbi.nlm.nih.gov/41561732/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41525043", "title": "Integrating IVF and Surgical Management in Endometriosis-Associated Infertility: A Review.", "authors": "Colombo GE et al.", "journal": "Advances in therapy", "date": "2026-03-30", "url": "https://pubmed.ncbi.nlm.nih.gov/41525043/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41518996", "title": "Targeted axillary dissection in breast cancer: current evidence and ongoing trials.", "authors": "Loi F et al.", "journal": "European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology", "date": "2026-03-30", "url": "https://pubmed.ncbi.nlm.nih.gov/41518996/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41504632", "title": "DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer.", "authors": "Jhaveri K et al.", "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41504632/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41501990", "title": "Current state of mammography-based artificial intelligence for future breast cancer risk prediction: a systematic review.", "authors": "Lowry KP et al.", "journal": "Journal of the National Cancer Institute", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41501990/", "sentiment": { "label": "negative", "score": -0.527, "confidence": 0.53 } }, { "source": "pubmed", "pmid": "41494919", "title": "Interventions to improve testing, linkage to care, and treatment for hepatitis C infection in prison: a systematic review and meta-analysis.", "authors": "Cunningham EB et al.", "journal": "The International journal on drug policy", "date": "2026-03-30", "url": "https://pubmed.ncbi.nlm.nih.gov/41494919/", "sentiment": { "label": "positive", "score": 0.421, "confidence": 0.42 } }, { "source": "pubmed", "pmid": "41428480", "title": "Effectiveness and Impact of Maternal RSV Immunization and Nirsevimab on Medically Attended RSV in US Children.", "authors": "Moline HL et al.", "journal": "JAMA pediatrics", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41428480/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41401234", "title": "Diagnostic accuracy and prognostic value of CMR in patients with suspected acute coronary syndrome: a meta-analysis.", "authors": "van Cauteren YJM et al.", "journal": "European heart journal. Cardiovascular Imaging", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41401234/", "sentiment": { "label": "positive", "score": 0.128, "confidence": 0.13 } }, { "source": "pubmed", "pmid": "41400940", "title": "Comparison of Minimum Inhibitory Concentration as Measured by Etests and Agar Dilution in Neisseria gonorrhoeae Isolates from North Carolina, 2018-2024.", "authors": "Manuel JA et al.", "journal": "Sexually transmitted diseases", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41400940/", "sentiment": { "label": "negative", "score": -0.511, "confidence": 0.51 } }, { "source": "pubmed", "pmid": "41385065", "title": "ASO Author Reflections: Improving Lymphedema Outcomes After Head and Neck Oncologic Surgery.", "authors": "Smith JD et al.", "journal": "Annals of surgical oncology", "date": "2026-03-30", "url": "https://pubmed.ncbi.nlm.nih.gov/41385065/", "sentiment": { "label": "positive", "score": 0.421, "confidence": 0.42 } }, { "source": "pubmed", "pmid": "41360078", "title": "Potential role of perceived discrimination and sociodemographics on racial disparities in breast cancer symptom burden.", "authors": "Hu X et al.", "journal": "Journal of the National Cancer Institute", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41360078/", "sentiment": { "label": "negative", "score": -0.807, "confidence": 0.81 } }, { "source": "pubmed", "pmid": "41346093", "title": "Morphologic Evaluation of Hyperchromatic Crowded Groups Present in Cervical Thin Prep Cytology Tests as Identified by the Hologic Genius Digital Diagnostics System: A Descriptive Study.", "authors": "Harinath L et al.", "journal": "Diagnostic cytopathology", "date": "2026-03-30", "url": "https://pubmed.ncbi.nlm.nih.gov/41346093/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41343893", "title": "Multi-centre clinical validation of the NeuMoDx HPV assay for ASC-US / LSIL triage.", "authors": "Chin T et al.", "journal": "Diagnostic microbiology and infectious disease", "date": "2026-03-30", "url": "https://pubmed.ncbi.nlm.nih.gov/41343893/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41343016", "title": "Qualitative Interviews on the Experience of Orally vs. Intramuscularly Administered Endocrine Therapy for Advanced Breast Cancer: Patient and Healthcare Provider Perspectives.", "authors": "Speck RM et al.", "journal": "Oncology and therapy", "date": "2026-03-30", "url": "https://pubmed.ncbi.nlm.nih.gov/41343016/", "sentiment": { "label": "negative", "score": -0.527, "confidence": 0.53 } }, { "source": "reddit", "subreddit": "getagraph", "title": "Buy Signal Hologic Inc - 27 Mar 2026 @ 13:07 -> USD75.60", "text": "Ticker: **HOLX**\n\nExchange: **NASDAQ**\n\nTime: **27 Mar 2026 @ 13:07**\n\nPrice: **USD75.60**\n\nLink: https://getagraph.com/NASDAQ/stock/live-signals/HOLX/ENG", "author": "jvc72", "score": 1, "num_comments": 0, "date": "2026-03-27", "url": "https://reddit.com/r/getagraph/comments/1s5a8b2/buy_signal_hologic_inc_27_mar_2026_1307_usd7560/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "getagraph", "title": "Buy Signal Hologic Inc - 25 Mar 2026 @ 15:52 -> USD75.59", "text": "Ticker: **HOLX**\n\nExchange: **NASDAQ**\n\nTime: **25 Mar 2026 @ 15:52**\n\nPrice: **USD75.59**\n\nLink: https://getagraph.com/NASDAQ/stock/live-signals/HOLX/ENG", "author": "jvc72", "score": 1, "num_comments": 0, "date": "2026-03-25", "url": "https://reddit.com/r/getagraph/comments/1s3lcvw/buy_signal_hologic_inc_25_mar_2026_1552_usd7559/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "getagraph", "title": "Buy Signal Hologic Inc - 24 Mar 2026 @ 12:11 -> USD75.51", "text": "Ticker: **HOLX**\n\nExchange: **NASDAQ**\n\nTime: **24 Mar 2026 @ 12:11**\n\nPrice: **USD75.51**\n\nLink: https://getagraph.com/NASDAQ/stock/live-signals/HOLX/ENG", "author": "jvc72", "score": 1, "num_comments": 0, "date": "2026-03-24", "url": "https://reddit.com/r/getagraph/comments/1s2i9lf/buy_signal_hologic_inc_24_mar_2026_1211_usd7551/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "getagraph", "title": "Buy Signal Hologic Inc - 24 Mar 2026 @ 10:25 -> USD75.44", "text": "Ticker: **HOLX**\n\nExchange: **NASDAQ**\n\nTime: **24 Mar 2026 @ 10:25**\n\nPrice: **USD75.44**\n\nLink: https://getagraph.com/NASDAQ/stock/live-signals/HOLX/ENG", "author": "jvc72", "score": 1, "num_comments": 0, "date": "2026-03-24", "url": "https://reddit.com/r/getagraph/comments/1s2fazv/buy_signal_hologic_inc_24_mar_2026_1025_usd7544/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "getagraph", "title": "Buy Signal Hologic Inc - 20 Mar 2026 @ 12:24 -> USD75.50", "text": "Ticker: **HOLX**\n\nExchange: **NASDAQ**\n\nTime: **20 Mar 2026 @ 12:24**\n\nPrice: **USD75.50**\n\nLink: https://getagraph.com/NASDAQ/stock/live-signals/HOLX/ENG", "author": "jvc72", "score": 1, "num_comments": 0, "date": "2026-03-20", "url": "https://reddit.com/r/getagraph/comments/1rz0y4s/buy_signal_hologic_inc_20_mar_2026_1224_usd7550/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "getagraph", "title": "Buy Signal Hologic Inc - 12 Mar 2026 @ 12:47 -> USD75.38", "text": "Ticker: **HOLX**\n\nExchange: **NASDAQ**\n\nTime: **12 Mar 2026 @ 12:47**\n\nPrice: **USD75.38**\n\nLink: https://getagraph.com/NASDAQ/stock/live-signals/HOLX/ENG", "author": "jvc72", "score": 1, "num_comments": 0, "date": "2026-03-12", "url": "https://reddit.com/r/getagraph/comments/1rrw35b/buy_signal_hologic_inc_12_mar_2026_1247_usd7538/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "TDX_Roblox", "title": "HolX up", "text": "Was the x-3 Heli always 23k or did John nerf again", "author": "Spartan_enjoyer_XVI", "score": 3, "num_comments": 10, "date": "2026-03-29", "url": "https://reddit.com/r/TDX_Roblox/comments/1s70136/holx_up/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "MedicalDevices", "title": "Hologic", "text": "Hi everyone,\n\nI’m a Registered Nurse who is interviewing next week for a Surgical Territory Manager position in NY. A recruiter found me on LinkedIn. Just wondering if anyone has experience working for them (pros& cons), work/life balance, salary range, etc? \n\nThank you!", "author": "Infamous_Call_4810", "score": 2, "num_comments": 7, "date": "2026-03-13", "url": "https://reddit.com/r/MedicalDevices/comments/1rswbpx/hologic/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "MedicalDevices", "title": "Hologic Marketing", "text": "Wondering if anyone has any insights on the marketing culture at Hologic? It seems like there’s been a lot of turnover so I’m wondering if anyone has any background. Part of me wonders if the Blackstone/TPG purchase will help improve anything. Any insights would be great! Thanks! ", "author": "strong-Living-5960", "score": 1, "num_comments": 2, "date": "2026-03-26", "url": "https://reddit.com/r/MedicalDevices/comments/1s4lfo6/hologic_marketing/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "BMET", "title": "FE Hologic Question", "text": "Hey Team,\nDoing my first PM on a Hologic Mammo since I went to class a year ago. Can you help me out with this math formula that needs to be done?\n\nCalculate: (mR - Mean mR²)=\n\nThe class did not cover this.. \n\n", "author": "Legal_Cupcake_6579", "score": 2, "num_comments": 1, "date": "2026-03-25", "url": "https://reddit.com/r/BMET/comments/1s32q6o/fe_hologic_question/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "nightcafe", "title": "A cyberpunk cityscape unfolds in a narrow, bustling alley lit by flickering neon signs that bathe everything in an electric blue glow. Holog...", "text": "", "author": "One_Woodpecker766", "score": 4, "num_comments": 2, "date": "2026-03-13", "url": "https://reddit.com/r/nightcafe/comments/1rsqw0b/a_cyberpunk_cityscape_unfolds_in_a_narrow/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "MedTech", "title": "Hologic Marketing", "text": "", "author": "strong-Living-5960", "score": 1, "num_comments": 0, "date": "2026-03-26", "url": "https://reddit.com/r/MedTech/comments/1s4lhzm/hologic_marketing/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "MedTech", "title": "Hologic Marketing", "text": "", "author": "strong-Living-5960", "score": 1, "num_comments": 0, "date": "2026-03-26", "url": "https://reddit.com/r/MedTech/comments/1s4lfzu/hologic_marketing/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "DataAnalyst_com", "title": "Hologic is hiring a Senior BI Development Analyst with 5 - 10 years of experience | United States - .", "text": "", "author": "stopbanningmybot", "score": 1, "num_comments": 0, "date": "2026-03-20", "url": "https://reddit.com/r/DataAnalyst_com/comments/1rz99ly/hologic_is_hiring_a_senior_bi_development_analyst/", "sentiment": { "label": "positive", "score": 0.421, "confidence": 0.42 } }, { "source": "reddit", "subreddit": "fantasybooks", "title": "All of my SFF books ranked!", "text": "Hi everyone, do you have any recommendations for me based on what I like and dislike? I know I also included some lit-fic with sci-fi or fantasy elements, it's close enough!", "author": "Verrem", "score": 16, "num_comments": 96, "date": "2026-03-17", "url": "https://reddit.com/r/fantasybooks/comments/1rwma2x/all_of_my_sff_books_ranked/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "diypedals", "title": "One last itch I had to scratch...", "text": "Hey friendos.\n\nThe more time I spend studying, breadboarding, and building pedals, the more I find myself wanting for better tools...things that fit my work, feel good to use, and help me get through the labor of discovery with some measure of success. The truth is, I need these things because frankly, a guy like me needs all the help he can get. That and well, for me, free time and spare energy is becoming harder and harder to find. So when I do find some, I got to make it count.\n\nSo \"build bet", "author": "mongushu", "score": 203, "num_comments": 48, "date": "2026-03-21", "url": "https://reddit.com/r/diypedals/comments/1rzfn4t/one_last_itch_i_had_to_scratch/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "Edexcel", "title": "Official jan 2026 GB", "text": "", "author": "CustomerPurple7958", "score": 86, "num_comments": 76, "date": "2026-03-04", "url": "https://reddit.com/r/Edexcel/comments/1rkfkn1/official_jan_2026_gb/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "Emo", "title": "got into emo recently, these are my favorite records so far", "text": "in alphabetic order", "author": "Traverser_of_Route7", "score": 91, "num_comments": 59, "date": "2026-03-29", "url": "https://reddit.com/r/Emo/comments/1s71i8i/got_into_emo_recently_these_are_my_favorite/", "sentiment": { "label": "positive", "score": 0.459, "confidence": 0.46 } }, { "source": "reddit", "subreddit": "AnimeCollectors", "title": "Yard Sale Haul, Guy was charging $1 a disk", "text": "Had to hide myself foaming at the mouth ", "author": "PretendElevator2928", "score": 264, "num_comments": 35, "date": "2026-03-01", "url": "https://reddit.com/r/AnimeCollectors/comments/1rhlmc2/yard_sale_haul_guy_was_charging_1_a_disk/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "X4Foundations", "title": "Did you know they've been making this update for a while now?", "text": "", "author": "-Weslin", "score": 139, "num_comments": 27, "date": "2026-03-19", "url": "https://reddit.com/r/X4Foundations/comments/1ry2hmt/did_you_know_theyve_been_making_this_update_for_a/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "DarkPsychology101", "title": "Why smart people believe stupid things?", "text": "", "author": "true_rational_mind", "score": 99, "num_comments": 35, "date": "2026-03-04", "url": "https://reddit.com/r/DarkPsychology101/comments/1rkomsy/why_smart_people_believe_stupid_things/", "sentiment": { "label": "negative", "score": -0.178, "confidence": 0.18 } }, { "source": "reddit", "subreddit": "CBSE", "title": "This guy will save my sst single handedly", "text": "love you digraj sir 😭", "author": "Substantial-Bid-7821", "score": 109, "num_comments": 31, "date": "2026-03-05", "url": "https://reddit.com/r/CBSE/comments/1rl8qes/this_guy_will_save_my_sst_single_handedly/", "sentiment": { "label": "positive", "score": 0.494, "confidence": 0.49 } }, { "source": "reddit", "subreddit": "NIOS_Students", "title": "GUYSSSS I MADEEEE ITTTT AAGGGYIIII BOOKSSSS", "text": "YES IM THAT PERSON WHO KEPT SAYING KI ONE DAY ILL POST TS IT FEELS LIKE A FUCKING ACHIEVEMENT OH GOD 😭🙏", "author": "willyouhuntme", "score": 25, "num_comments": 37, "date": "2026-03-28", "url": "https://reddit.com/r/NIOS_Students/comments/1s5vr6z/guyssss_i_madeeee_itttt_aagggyiiii_bookssss/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "london", "title": "The anemometer or \"wind-dial\" connecting to a vane on the roof to show the wind's direction on a dial inside, made in 1694 and still in use at Kensington Palace, London", "text": "Shows the seas around England during the wars with France, to help predict fair winds for sailing the navy to battle. Includes ‘Groine’ (La Coruna) and ‘Silly’ (Scilly). It was designed by Robert Morden (c.1650–1703) for King William III and remains working and in situ in Kensington Palace. ", "author": "Big_Pool4238", "score": 311, "num_comments": 7, "date": "2026-03-29", "url": "https://reddit.com/r/london/comments/1s74z69/the_anemometer_or_winddial_connecting_to_a_vane/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } } ] } }